Recently Added |view more
Presented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education, this virtual CME is designed to help medical, radiation and surgical oncologists, gynecologists, radiologists, and primary care physicians ...
Amoroso is part of the nurse-led dedicated intravesical clinic that helps optimize treatment for patients and workflow for other physicians and nurses.
Hereditary cancer syndromes cause a significant portion of gynecologic malignancies. Many times, gynecologic cancers are diagnosed in the late stages, at a time when treatment options are limited.
Watch this short video on the three components of breast cancer screening—brought to you by Andrea Porpiglia, MD, MSc, FACS, Assistant Professor, Department of Surgical Oncology at Fox Chase.
The phase-1 trial will test a new targeted therapy called seclidemstat in patients with relapsed or refractory Ewing sarcoma or Ewing-related Sarcomas.
A partnership between the Fox Chase solid tumor oncologists and their colleagues in bone marrow transplantation tests the potential of adoptive cell therapies for the treatment of solid tumors.
Researchers at Fox Chase Cancer Center discuss the benefits of the PARP inhibitor olaparib for women with high-risk, HER2-negative, BRCA-mutant early breast cancer.
Fox Chase Cancer Center’s urologic oncology group shares an educational video that provides instruction on how to perform a device-free, free-handed transperineal prostate biopsy.
Join us for this virtual CME, where the Fox Chase Cancer Center genitourinary (GU) oncology team will discuss the many facets of prostate cancer management as well as the latest advances and treatments for treating this disease.
Two new collaborative publications focus on treatment decisions for patients with renal masses.
Three members of Fox Chase Cancer Center’s Genitourinary Cancer Program – Elizabeth Plimack, MD, MS; Alexander Kutikov, MD, FACS; and Benjamin Miron, MD -- have gained national recognition for their work advancing the care of patients ...
As patient care adapted to the restrictions of the COVID-19 pandemic, Farrell continued to ensure that patients had access to cutting-edge care.
Evaluating the current standards of care for cystectomy yielded interesting results on when it is most appropriate.
Jelmyto provides an alternative treatment option for low-grade UTUC and may spare some patients from nephrectomy. A recent study of the treatment showed a 58% complete response rate.
For the second year in a row, the Center for International Blood & Marrow Transplant Research (CIBMTR) has recognized the Fox Chase-Temple University Hospital Bone Marrow Transplant (BMT) Program as performing above expectations.